LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Cerrado

SectorSanidad

66.06 -4.62

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

65.73

Máximo

69.31

Métricas clave
By Trading Economics
Ingresos	24M -167M
Ventas	40M 195M
BPA	-0.84
Margen de beneficios	-85.626
Empleados	834
EBITDA	75M -105M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+56.47% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-706M 13B
Apertura anterior	70.68
Cierre anterior	66.06

Noticias sobre sentimiento de mercado

By Acuity

46%

54%

144 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

34.71 / 36.9 Soporte y Resistencia

Bridgebio Pharma Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2026, 22:47 UTC

Acciones populares

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 may 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 may 2026, 22:00 UTC

Principales Movimientos del Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 may 2026, 18:09 UTC

Principales Movimientos del Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 may 2026, 16:02 UTC

Ganancias

Principales Movimientos del Mercado

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 may 2026, 14:55 UTC

Principales Movimientos del Mercado

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 may 2026, 14:43 UTC

Principales Movimientos del Mercado

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 may 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 may 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 may 2026, 21:16 UTC

Charlas de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 20:19 UTC

Acciones populares

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 may 2026, 19:41 UTC

Adquisiciones, fusiones, absorciones

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 may 2026, 19:35 UTC

Charlas de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 may 2026, 18:35 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 may 2026, 17:28 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 may 2026, 16:24 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 may 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 15:55 UTC

Charlas de Mercado

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 may 2026, 15:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2026, 15:20 UTC

Charlas de Mercado

Silver Plunges on Inflation Worries -- Market Talk

15 may 2026, 15:20 UTC

Ganancias

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 may 2026, 14:33 UTC

Charlas de Mercado

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparación entre iguales

Cambio de precio

Bridgebio Pharma Inc previsión

Precio Objetivo

By TipRanks

56.47% repunte

Estimación a 12 Meses

Media 109 USD 56.47%

Máximo 157 USD

Mínimo 94 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bridgebio Pharma Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

17 ratings

Comprar

Mantener

Vender

De acuerdo con 17 analistas que ofrecen calificaciones bursátiles a para Bridgebio Pharma Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

34.71 / 36.9Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

144 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.